sabato, 4 dicembre 2021
3 Settembre 2019

FDA Delays Decision on Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

Aug 30, 2019 – The FDA has extended the review period for a supplemental biologics license application (sBLA) for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) who do not have EGFR or ALK aberrations. Roche (Genentech), the manufacturer of the PD-L1 inhibitor atezolizumab, reported in a press release that the extension … (leggi tutto)